The majority of patients may safely take glucagon-like peptide 1 receptor agonists (GLP-1 RAs) before elective surgery and ...

Recent studies have shown that pharmacological treatment with GLP-1-RA and dual GLP-1/glucose-dependent insulinotropic ...

A large retrospective study, the first of its kind, reported reduced rates of EO-CRC in patients younger than 50 years of age ...

Recently the U.S. Food and Drug Administration (FDA) issued updated safety warnings for all glucagon-like peptide 1 receptor ...

Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity.

Most patients should not stop taking GLP-1 receptor agonists prior to elective surgery, according to updated guidance from ...

The GLP-1 RA cohort had significantly lower odds of developing early-onset colorectal cancer (0.4 vs 0.7%) vs the no GLP-1 RA cohort. HealthDay News — Glucagon-like peptide-1 receptor agonists ...

There's a new player in the running game, and it's not the latest carbon-plated shoe or fancy GPS watch. GLP-1 medications ...

Drugs such as Wegovy, Ozempic, and Saxenda have quickly become household names. But are these weight loss medications right ...

Between 2022 and 2023, prescriptions for GLP-1 drugs soared 132.6% while bariatric surgery rates fell 25.6%, according to a new study from researchers at Boston-based Harvard Medical School and ...

Recommendations are presented for the safe use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the perioperative period.